You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Amino acid derived urea based chemicals as sEH inhibitor
SBC: Arete Therapeutics, Inc. Topic: N/ADESCRIPTION (provided by applicant): Recent findings indicate that increasing levels of epoxides of arachidonic acid (EETs) appear to be new and excellent means to treat both hypertension and vascular inflammation. We demonstrated that in vivo inhibition of soluble epoxide hydrolase resulted in higher levels of EETs and in reduction of blood pressure and inflammation in animal models. Because the ...
STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health -
Novel epoxide hydrolase inhibitor for stroke prevention
SBC: Arete Therapeutics, Inc. Topic: N/ADESCRIPTION (provided by applicant): A major cause of morbidity and mortality is the progression of organ damage associated with cardiovascular diseases. For instance, the incidence of stroke and costs associated with stroke damage continues to have a devastating impact on public health despite numerous treatments aimed at cardiovascular risk factors. Recent findings indicate that increasing lev ...
STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health -
USING AL TO ENHANCE VR ANXIETY DISORDER TREATMENT
SBC: ARGUS VR INTERNATIONAL Topic: N/ADESCRIPTION (provided by applicant) This project will develop an artificial intelligence to provide the core functionality for virtual reality and computer based treatments for anxiety disorders. The use of artificial intelligence offers a number of advantages over existing treatments: (1) artificial intelligence provides personalized treatment - using multiple real time physiologic and subjective ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
Quantitation Pulmonary Delivery of Therapeutic Protein
SBC: Arizeke Pharmaceuticals, Inc. Topic: N/ADESCRIPTION (provided by applicant): Arizeke Pharmaceuticals, Inc. is focused on the pulmonary delivery of protein therapeutics (including antibodies) to treat pulmonary disease. Arizeke's technology provides a unique ability to deliver large therapeutic proteins into the lung parenchyma and interstitium and into the lymphatic drainage system. Examples of indications that can be targeted by this t ...
STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health -
Safety of intraarticular N-acetylglucosamine
SBC: ARTYX PHARMACEUTICALS, INC. Topic: N/ADESCRIPTION (provided by applicant): Osteoarthritis (OA) is the most prevalent joint disease, causing joint pain and dysfunction. OA is also associated with substantial co-morbidity and reduces life expectancy. Pharmacologic therapy is limited to symptom modification and disease-modifying therapies are currently not available. Furthermore, even symptom-modifying therapies are limited in efficacy a ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
Radiosensitization by modulating inhibitors of apoptosis
SBC: Ascenta Therapeutics, Inc. Topic: N/ADESCRIPTION (provided by applicant): Radioresistance markedly impairs the efficacy of tumor radiotherapy and involves anti-apoptotic signal transduction pathways that prevent radiation-induced cell death. The inhibitors of apoptosis proteins (IAP) are important intrinsic cellular inhibitors of apoptosis, highly expressed in prostate and lung cancer cells, and play an important role in resistance ...
STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health -
A targeted peptide for PET imaging of cancer
SBC: ATTENUON, LLC Topic: N/ADESCRIPTION (provided by applicant): ATN-161 (Ac-PHSCN-NH2) is a five amino acid peptide with potent anti-tumor, anti-angiogenic and anti-metastatic activity that specifically localizes to tumor cells and tumor endothelium. ATN-1 61 binds to several fully activated integrins which are involved in angiogenesis, metastasis and tumor growth and are present in both tumor and angiogenic endothelial ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Tooth Phone Auditory Device TPAD
SBC: Audiodontics LLC Topic: N/ADESCRIPTION (provided by applicant): TOPIC - Tooth Phone(R) Auditory Device - TPAD ABSTRACT The Tooth Phone(R) Auditory Device - TPAD is new alternative device to the only direct bone conduction hearing aid currently accepted by the Food and Drug Administration (FDA) for the treatment of certain specific types of hearing loss. Unlike the precedent FDA approved device that uses an osseointegrated i ...
STTR Phase I 2009 Department of Health and Human ServicesNational Institutes of Health -
AEGIS: A Pixel-array Readout IC for Gamma-ray Imaging
SBC: Augustine Engineering Topic: N/ADESCRIPTION (provided by applicant): CdZnTe arrays are promising detectors for improving nuclear medicine imaging, but existing CdZnTe cameras have limited spatial resolution and small numbers of pixels (space bandwidth product = SpBW). We show that major performance improvements will require high SpBW (>10A5) and small pixels (high resolution). The best approach to obtaining high SpBW detectors i ...
STTR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health -
Novel lipid-based therapies for cystic fibrosis
SBC: AVRION MOLECULAR, INC. Topic: N/ADESCRIPTION (provided by applicant): Although the genetic cause of cystic fibrosis (CF), a lethal autosomal disorder, has been known for over a decade, an effective therapeutic method is still lacking. Pulmonary disease remains the major cause of morbidity and mortality in CF. The CF lung is marked by dysregulated inflammation and chronic infection, the end result being progressive bronchiectatic ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health